Date: January 28, 2005
Place: Building 45, Conference Room E1&E2
National Institutes of Health
Bethesda, Maryland 20892
The 178th meeting of the National Advisory Dental and Craniofacial Research Council (NADCRC) was convened on January 28, 2005, at 8:30 a.m., in Building 45, Conference Room E1&2, National Institutes of Health (NIH), Bethesda, Maryland. The meeting was open to the public from 8:30 a.m. to 10:50 a.m., followed by the closed session for Council business and consideration of grant applications from 1:00 p.m. until adjournment at 4:00 p.m. Dr. Lawrence A. Tabak presided as Chair.
Members Present:
Dr. Eli I. Capilouto
Dr. Louise T. Chow
Dr. Nereyda P. Clark
Dr. Matthew J. Doyle
Dr. Augusto R. Elias-Boneta
Dr. Linda G. Griffith
Dr. Mark C. Herzberg
Dr. Josephine Lai
Dr. Jon D. Levine
Dr. Anne S. Lindblad
Dr. Francis L. Macrina
Dr. Harold Morris
Dr. Michael J. Reed
Dr. Jonathan P. Schuermann
Dr. George W. Taylor, Jr.
Members of the Public Present:
Dr. Linda Bonewald, Lefkowitz Professor, School of Dentistry, University of Missouri-Kansas City, and Chair, NIDCR Board of Scientific Counselors
Mr. Jack Bresch, Associate Executive Director, American Dental Education Association (ADEA), Washington, DC
Dr. Aida A. Chohayeb, Women Network Collective Research, Washington, DC
Dr. Robert J. (Skip) Collins, Deputy Executive Director, International Association for Dental Research (IADR) and American Association for Dental Research (AADR), Alexandria, VA
Dr. Christopher H. Fox, Executive Director, IADR and AADR, Alexandria, VA
Dr. Frank A. Kyle, Jr., Manager, Legislative and Regulatory Policy, American Dental Association (ADA), Washington, DC
Ms. Gina Luke, Director, State Government Relations and Advocacy Outreach, ADEA, Washington, DC
Ms. Monette McKinnon, Director, Grassroots Advocacy and State Issues, ADEA, Washington, DC
Ms. Myla Moss, Director, Congressional Relations, ADEA, Washington, DC
Dr. Eileen Resnick, Scientific Program Manager, Society for Women’s Health Research, Washington, D.C.
Ms. Robin Taller, Writer/Editor, Constella Group, Bethesda, MD
Federal Employees Present:
National Institute of Dental and Craniofacial Research:
Dr. Lawrence A. Tabak, Director, NIDCR
Dr. Imad Al-Dakkak, Resident, Division of Clinical Research and Health Promotion (DCRHP)
Dr. Robert C. Angerer, Scientific Director, Division of Intramural Research (DIR)
Ms. Carolyn Baum, Committee Management Specialist and Council Secretary, Office of the Director (OD)
Dr. Sangeeta Bhargava, Health Scientist Administrator and Program Director, Immunology and Immunotherapy Program, Division of Basic and Translational Sciences (DBTS)
Dr. Henning Birkedal-Hansen, Acting Deputy Director, NIDCR
Dr. Norman S. Braveman, Executive Secretary, NADCRC, and NIDCR Board of Scientific Counselors, and Assistant to the Director, OD
Ms. María Teresa Canto, Health Scientist Administrator and Program Director, Population Studies Program, DCRHP
Dr. Natalia Chalmers, Special Volunteer, Oral Infection and Immunity Branch, DIR
Dr. Lois K. Cohen, Associate Director for International Health, NIDCR, and Director, Office of International Health (OIH)
Mr. George J. Coy, Chief, Financial Management Branch (FMB), Office of Administrative Management (OAM)
Ms. Mary Daley, Chief Grants Management Officer, Grants Management Branch (GMB), Division of Extramural Activities (DEA)
Mr. Jimmy Do, Budget Analyst, FMB, OAM
Ms. Yvonne H. du Buy, Associate Director for Management, and Chief, OAM
Dr. Isabel Garcia, Acting Director, Office of Science Policy and Analysis (OSPA), and Co-Director, Residency Program in Dental Public Health at NIDCR, DCRHP
Ms. Christen Geiler, Computer Specialist, Office of Information Technology (OIT), OD
Dr. Kevin Hardwick, International Health Officer, OIH, and Special Assistant for Research Infrastructure and Curriculum Development, OD
Dr. H. George Hausch, Acting Director, DEA
Dr. Rosemarie Hunziker, Director, Technology Development and Industrial Relations Program, Center for Biotechnology and Innovation (CBI)
Ms. Lorrayne Jackson, Extramural Research Analyst and Outreach Specialist, OD
Dr. Eleni Kousvelari, Director, CBI
Dr. John W. Kusiak, Health Scientist Administrator and Program Director, Molecular and Cellular Neurobiology Program, DBTS
Ms. Carol Loose, Budget Analyst, FMB, OAM
Dr. Dennis F. Mangan, Acting Deputy Director, DBTS, and Chief, Infectious Diseases and Immunity Branch, DBTS
Ms. Amy McGuire, Grants Management Specialist, GMB, DEA
Dr. Richard L. Mowery, Chief, Clinical Research Branch, DCRHP
Dr. Ruth Nowjack-Raymer, Health Scientist Administrator and Program Director, Health Disparities Research Program, DCRHP
Ms. Helen Pham, Grants Management Specialist, GMB, DEA
Dr. Bruce L. Pihlstrom, Acting Director, DCRHP
Dr. Pamela Gehron Robey, Chief, Craniofacial and Skeletal Diseases Branch, DIR
Ms. Rebecca Roper, Scientific Review Administrator, DEA
Ms. Diana Rutberg, Grants Management Specialist, GMB, DEA
Dr. Ann L. Sandberg, Acting Director, DBTS
Dr. Yasaman Shirazi, Health Scientist Administrator and Program Director, Epithelial Cell Regulation and Transformation Program, DBTS
Dr. Lillian Shum, Health Scientist Administrator and Program Director, Physiology, Pharmacogenetics, and Injury Program, DBTS
Dr. Rochelle Small, Health Scientist Administrator and Program Director, Developmental Biology and Mammalian Genetics Program, DBTS
Ms. Traci Walker, Committee Management Assistant, OD
Other Federal Employees:
Dr. Daniel Lerman, Health Policy Analyst, Office of Science Policy, Office of the Director, NIH
Dr. William Maas, Director, Division of Oral Health, Centers for Disease Control and Prevention, Chamblee, GA
OPEN PORTION OF THE MEETING
I. CALL TO ORDER
Dr. Lawrence A. Tabak, Director, NIDCR, called the meeting to order. Dr. Tabak welcomed three new Council members: Drs. Augusto R. Elias-Boneta, Anne S. Lindblad, and Jon D. Levine. He thanked Dr. Jonathan P. Schuermann for serving as an ad hoc member of the Council beginning when he was a graduate student. Dr. Schuermann recently received a Ph.D. and will continue his studies of structural crystallography at the University of Texas at San Antonio.
Dr. Tabak invited the Council members and guests to introduce themselves. He thanked the Council members for their words of encouragement to him during a recent family illness.
II. APPROVAL OF MINUTES
The minutes of the Council’s meeting on September 28, 2004, were considered and unanimously approved.
III. OPERATING PROCEDURES
The Council unanimously concurred with the rules governing the Council’s operating procedures.
IV. FUTURE COUNCIL MEETING DATES
The following dates for future Council meetings were confirmed:
June 10, 2005
September 23, 2005
January 23, 2006
May 22, 2006
September 18, 2006
V. REPORT OF THE DIRECTOR
Dr. Tabak presented an overview of NIDCR activities and scientific advances since the previous Council meeting. He highlighted items from the written Director’s Report (see Attachment III).
Activities
NIDCR Director and Acting Deputy Director. Dr. Tabak reported that he continued his active schedule of meetings at dental schools and professional organizations and with research groups to discuss the NIH Roadmap and future research directions at NIDCR. Dr. Henning Birkedal-Hansen, Acting Deputy Director, continued to guide the development of the Implementation Plan for the NIDCR Strategic Plan. These activities and those of Dr. Dushanka Kleinman, Chief Dental Officer, U.S. Public Health Service, are described in the written Director’s Report.
Implementation of the NIDCR Strategic Plan. Development of the Implementation Plan continues under the leadership of Dr. Birkedal-Hansen. The NIDCR has convened five working group sessions, including two that were held on January 27, just before the Council meeting. (See section IX below for additional details.)
Oral Mucosal Immunity Research Meeting. The NIDCR hosted a meeting in October 2004 to evaluate and discuss NIDCR future directions in oral mucosal immunity research. (See section VIII below for additional details.)
Student Loan Repayment. In Fiscal Year (FY) 2004, the NIH awarded student loan repayment contracts to more than 1,400 health researchers in the United States. The NIDCR funded 14 of these individuals, 9 of whom had a D.D.S. or D.M.D. degree or combined D.D.S.-Ph.D. or D.M.D.-Ph.D. degree. Dr. Tabak noted that the NIH Loan Repayment Programs can repay up to $35,000 of qualified educational debt each year for 3 years, totaling up to $105,000, for health professionals pursuing careers in clinical, pediatric, contraception and infertility, or health disparities research. He encouraged the Council members to help advertise the availability of these programs. Online information is available at: http://www.lrp.nih.gov/about/5lrps.htm
NIH Director’s Pioneer Award. The NIH recently announced the opening of the 2005 NIH Director’s Pioneer Award program. Scientists at all career levels are eligible to apply for the program by self-nomination. Dr. Tabak encouraged the Council members to nominate themselves for this award. Information about the award and nomination process is available at: http://nihroadmap.nih.gov/pioneer.
New NIH Roadmap Initiatives. Dr. Tabak reported that NIDCR staff were able to integrate oral health into two recent research training initiatives: (i) Predoctoral Clinical Research Training Programs (a T32 National Research Service Award), and (ii) Multidisciplinary Clinical Research Career Development Programs (a K12 Mentored Clinical Scientist Development Program Award). A workshop to describe the request for applications (RFA) for each initiative will be videocast on February 2. Drs. Kevin Hardwick and Bruce Pihlstrom are the NIDCR contacts. Dr. Tabak encouraged the Council members and their colleagues to apply for these institutional resources.
Grant Preparation Workshop for Dental Faculty. On April 18–19, the NIDCR will host an NIH Grants Workshop for Tenure-Track or Recently Tenured Dental School Faculty. Dr. Tabak noted that the NIDCR will support the travel and lodging of up to three faculty members from each dental school. The NIDCR has informed the deans of dental schools about this workshop and has asked dental leaders to nominate individuals to attend this grant-preparation workshop. Dr. Kevin Hardwick is the NIDCR contact.
Scientific Advances
Dr. Tabak highlighted three published scientific advances.
Use of Saliva to Detect Oral Cancer. NIDCR-funded scientists have established that salivary secretions can be used to measure elevated levels of four distinct cancer-associated molecules in saliva. This “proof-of-principle” study is the first to show that distinct patterns of messenger RNA are measurable in saliva and can indicate a developing tumor.
Functional Imaging and Pain Processing. NIDCR-supported researchers have shown that functional magnetic imaging (fMRI) techniques can be used to assess human nociception non-invasively in the trigeminal system and may be useful clinically for evaluating normal and abnormal neural processing in individuals with chronic orofacial pain.
Dental Caries in Immigrant Children. A team of NIDCR grantees and colleagues have reported on a survey of the prevalence of dental caries in more than 200 immigrant children who recently arrived in the United States. One of the interesting findings noted is that the refugee children from Africa had significantly lower dental caries and fewer untreated caries than the refugee children of similar ages from Eastern Europe.
VI. DIRECTOR’S BUDGET REPORT
Dr. Tabak discussed the NIDCR budget for FY 2004 and FY 2005 and plans for the future.
FY 2004. The NIDCR budget totaled approximately $382 million. Of this, approximately $308 million was allocated for extramural research, $54 million for intramural research, and $20 million (or about 5 percent) for research management and support.
Approximately $232 million (or 78 percent of the total funds) supported 681 extramural research project grants (RPGs). Dr. Tabak noted that the payline for RPGs was 26.4 percent, and the success rate was 29.7 percent, which is slightly higher than the NIH average. The total for intramural research includes funding for actual research activities (approximately $37 million) and for some central NIH assessments (e.g., rent, management) and renovation of NIDCR laboratories. The total amount for all central NIH assessments was approximately $32 million.
Approximately 9 percent of the total NIDCR funds supported research training and career development. Dr. Tabak commented that the NIDCR supported 38 postdoctoral, 2-year Individual Scholar Development and Faculty Transition Awards (K22s) and that this significant investment was made in response to the difficulties noted by dental school deans in recruiting research faculty. Approximately 4 percent of total funds supported seven research centers, and 3 percent supported infrastructure development at seven dental schools.
Dr. Tabak noted that 22 percent of the total funds was discretionary (available for new initiatives) and 78 percent was already committed (e.g., to ongoing grants, contracts, operating expenses). With the discretionary funds, the NIDCR was able to increase clinical research; capitalize on advances in bioengineering, genomics, and proteomics; and support HIV/AIDS research. In each area, the NIDCR issued RFAs or program announcements (PAs) to stimulate research. The funded initiatives in clinical research included, for example, Phase III Clinical Trials in Oral Infectious Diseases, Epidemiological and Behavioral Research in Oral Health, and NIDCR Exploratory and Developmental Grants in Clinical Research. Funded initiatives to capitalize on advances in technology included, for example, The Salivary Proteome: Catalogue of Salivary Secretory Components and Specialized Centers for Oral, Dental, and Craniofacial Research. In HIV/AIDS research, the NIDCR supported two initiatives: Oral Mucosa and HIV Infection, and Simian Models for the Oral Biology of HIV Infection and AIDS.
FY 2005. The NIDCR budget for this year totals approximately $392 million. The NIDCR will contribute approximately $2.5 million to NIH Roadmap activities. Dr. Tabak noted that the projected success rate of 24–25 percent will be a “soft landing” from the recent doubling of the NIH budget over 5 years. He emphasized that the NIDCR is “forging ahead” with its top priority, to increase clinical research. He noted that three of the funded initiatives will significantly strengthen the NIDCR position in clinical research: Practice-Based Research Network, Prospective Studies on Craniofacial Pain and Dysfunction, and Clinical Research Training Initiative. When combined with NIH Roadmap initiatives, these efforts offer a robust set of opportunities for clinical research training.
To capitalize on advances in bioengineering, genomics, and proteomics, the NIDCR is supporting two initiatives: Mechanisms of Orofacial Pain: Anatomy, Genomics, Proteomics, and Regenerative Dental Medicine. Initiatives in HIV/AIDS research include, for example, AIDS-Related Oral Malignancies and Tumors.
FY 2006 and Plans for the Future. The President’s Budget for FY 2006 will be released to the Congress in early February 2005. For future planning, the NIDCR has requested, on its Web site, public input on the development of proposed research initiatives for FY 2007. Comments should be made by March 18, 2005, at http://www.nidcr.nih.gov. Dr. Tabak encouraged the Council members and their colleagues to provide input.
Dr. Tabak said that the NIDCR is planning aggressively for the future to take advantage of the many excellent research opportunities available. He anticipated that the NIDCR will have a significant leadership role in, for example, validating new technologies for clinical assessment of enamel demineralization, delineation of the role of neuronal–glial cell interactions in orofacial pain disorders, phase II trials of salivary diagnostics, modeling complex diseases such as Sjögren’s syndrome, bridging biology and materials science to “build” a tooth, and establishing the protein profiles of oral mucosal tissues in patients with HIV/AIDS.
Discussion
Discretionary Funds. The Council asked about the proportions of committed and discretionary funds. Dr. Tabak said that, to maintain flexibility to fund new initiatives, the NIDCR is shifting away from programs that involve a long commitment, but will continue to support some large, focused programs, such as the effort to build a tooth. He noted that, because discretionary funds are approximately 20 percent ($50–$70 million) of the budget, the NIDCR must continue to prioritize its efforts in consultation with the Council. He encouraged the Council and extramural scientists to help NIDCR identify research successes and advances and, thereby, “build the case” for increased funding of NIDCR research and discovery. An increased investment in NIDCR research would complement efforts to strengthen the dental research infrastructure and to develop rigorous systems for evaluating progress.
Research—Policy. The Council commented on the need for interface between research and policy. Dr. Tabak suggested that patient advocacy groups could provide an interface. The NIDCR has responsibility for gaining acceptance of research findings by practicing dentists (translational research) and interfaces informally with organizations within the U.S. Department of Health and Human Services that focus on policies.
Practice-Based Research Network. Asked to comment on the role of the network, Dr. Tabak said that the network would enable scientists to address research questions pertinent to dental practice, to clarify disease patterns, and to catalyze enhanced interactions between community practitioners and academic health centers. He noted that the program is experimental, promising, and timely and that the NIDCR will monitor and evaluate it carefully. Practitioners have indicated interest in developing a network, and the NIDCR investment will be important for integrating dentistry into the NIH Roadmap’s practice-based research networks.
VII. BIENNIAL ADVISORY COUNCIL REPORT ON TRACKING AND INCLUSION OF WOMEN
AND MINORITIES CLINICAL RESEARCH
Dr. Richard L. Mowery, Chief, Clinical Research Branch, Division of Clinical Research and Health Promotion, presented, for Council’s approval, the 2005 Biennial Advisory Council Report Certifying Compliance with the NIH Policy on Inclusion Guidelines. The report documents NIDCR activities in FY 2003–04 to ensure that women and minorities were included as subjects in clinical research. The NIDCR mailed the report to all Council members for their review prior to the meeting.
This biennial report is congressionally mandated. As stipulated by the NIH Revitalization Act of 1993, the advisory councils of each NIH institute or center (IC) must prepare a biennial report describing the activities of staff to comply with the Act, as well as results of these activities as reflected in enrollment statistics.
Dr. Mowery noted that approximately 52 percent of the participants enrolled in NIDCR-supported clinical research projects, including phase III clinical trials, were women, a percentage that is comparable to the percentage of women in the U.S. population. He further reported that approximately 20 percent of the participants reported their ethnicity as Hispanic or Latino. This percentage is higher than the average across the NIH.
The Council approved the report unanimously and concurred with its submission to the Office for Research on Women’s Health for inclusion in the NIH report submitted to Congress.
VIII. CONCEPT CLEARANCE: CONTROLLED DRUG DELIVERY FOR PREVENTION/TREATMENT OF
OROFACIAL DISEASE
Dr. Eleni Kousvelari, Director, Center for Biotechnology and Innovation, presented a proposed PA for drug delivery systems for treatment of orofacial disease. The purpose of the initiative is to “jump start” and enhance research and development on delivery systems for rapid and/or sustained, on-demand release of therapeutic agents (e.g., antimicrobial, anti-inflammatory) in the oral cavity. These agents would be used to treat oral diseases and conditions such as caries, periodontal disease, oral mucositis, temporomandibular joint and muscle disorders, and chronic pain. Current treatments are not always effective. Formulations are generally for systemic administration and may not be stable in the oral cavity. Having a site-specific drug delivery system is important. The effort would be supported by federally mandated set-aside funds under the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Research (STTR) programs. These NIDCR programs currently support only five grants in this area. Other NIH components have expressed interest in this effort, as have private companies, and the NIDCR hopes to stimulate a trans-NIH PA.
The Council agreed that this initiative is very important and will address significant clinical issues. The members encouraged the NIDCR to structure a balance between research on new materials and research on practical applications of materials that are already available.
The Council unanimously approved the concept.
IX. REPORT FROM ORAL MUCOSAL IMMUNITY PLANNING MEETING
Dr. Sangeeta Bhargava, Health Scientist Administrator and Program Director, Immunology and Immunotherapy Program, Division of Basic and Translational Sciences, reported on the NIDCR Oral Mucosal Immunology Advisory Meeting, held at the NIH on October 25–26, 2004. The purpose of the meeting was to review the current NIDCR portfolio of extramural research on the oral mucosal immune system (OMIS) within the context of contemporary approaches to studying the mucosal immune system in general.
The participants recommended research questions to address, identified research areas and scientific opportunities that are inadequately supported by NIDCR, and identified research opportunities related to the NIDCR mission. They highlighted the following two research questions as high priority: (1) What is the cellular and molecular composition of OMIS? (2) What are the key host genes that compose the OMIS? Two additional questions of equal, but less, priority are: (3) What endogenous and exogenous factors stimulate or suppress the immune response in the oral cavity? (4) What are the mechanisms involved in the regulatory systems that control the OMIS?
Dr. Bhargava cited specific research recommendations for each question. In addition, she noted three ways to advance research on OMIS: establishing collaborations and partnerships, ensuring access to research resources, and attracting mucosal immunologists to the study of oral immunity.
Dr. Mark Herzberg, who represented the Council at the meeting, reported that the participants were a compelling group that presented different points of view. He noted that the recommendations relate closely to the NIDCR proposed initiatives for FY 2007 in that most of the initiatives rely on answers to the four research questions. Dr. Herzberg noted that current knowledge of oral immunity is derived from studies of cells in sterile situations (cultures) or studies of gastrointestinal immunity. He urged the NIDCR to consider proposing a separate initiative that encompasses the specific recommendations for research questions 1 and 2 into the NIDCR plans for FY 2007.
Discussion
The Council suggested that the NIDCR consider emphasizing research question 3, simultaneously with questions 1 and 2, because of its implications for translational interventions. Dr. Tabak noted that oral mucosal immunity is central to the NIDCR mission and that the National Institute of Allergy and Infectious Diseases is supportive of NIDCR research in this area.
X. UPDATE ON PROGRAM PLANNING WORKING GROUPS
Dr. Birkedal-Hansen presented an update on the development of the Implementation Plan for the NIDCR Strategic Plan. In this process, the NIDCR is reviewing each program area to identify the highest priorities for funding over the next 5 years. Dr. Birkedal-Hansen noted that although the NIDCR is a small Institute, it covers “a lot of biology on a small budget.”
For each program review, the NIDCR convenes a working group composed of NIDCR staff, members of the NADCRC and the NIDCR Board of Scientific Counselors, and selected outside experts in the program area. Prior to the meeting, staff summarize the NIDCR portfolio in the area and send background materials to the working group. The meetings involve a 2–3 hour discussion of priorities for funding.
To date, the NIDCR has convened the following five working groups: Working Group on Microbiology and Immunology, Working Group on Head and Neck Cancer, Working Group on Craniofacial Development Biology and Bone Research, Working Group on Saliva Research and Sjögren’s Syndrome, and Working Group on Tissue Engineering, Biomaterials, Nanotechnology, and Industry Collaboration. The last two groups met on January 27, before the NADCRC meeting. Whenever possible, all meetings are held in conjunction with NADCRC meetings.
The NIDCR will convene five additional working groups. Three working groups (on pain, pharmacogenetics, and AIDS research) will meet in late March, and two working groups (on behavioral research and health disparities) will meet thereafter. The NIDCR will reassess separately its research training and career development programs.
XI. NEW NIH REVIEW CRITERIA FOR CLINICAL RESEARCH
Dr. Bruce Pihlstrom, Acting Director, Division of Clinical Research and Health Promotion, reported on the new NIH review criteria for clinical research. Reviews of all NIH criteria for funding are part of the NIH Roadmap activities. Suggested modifications to criteria are extensively discussed internally and externally, presented to the IC directors for acceptance, advertised in the NIH Guide, and then implemented for the review of research grant applications.
The new review criteria for clinical research were accepted by the IC directors in August 2004 and advertised in the NIH Guide on October 2004. They will take effect during the summer of 2005. Dr. Pihlstrom distributed a 1-page handout that listed the changes in comparison with the previous criteria which were adopted in 1997. He noted that the rewording broadens definitions, includes clinical practice and new technologies, and incorporates emphases in the NIH Roadmap (e.g., innovation, interdisciplinary research). Dr. Pihlstrom urged the Council members to note the new criteria.
Discussion
The Council suggested that the greater emphasis given to innovation in the new criteria may encourage investigators to “take a chance” and apply for funding of innovative research.
CLOSED PORTION OF THE MEETING
This portion of the meeting was closed to the public in accordance with the determination that it was concerned with matters exempt from mandatory disclosure under Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).
There was a discussion of procedures and policies regarding voting and confidentiality of application materials, committee discussions, and recommendations. Members absented themselves from the meeting during discussion of and voting on applications from their own institutions, or other applications in which there was a potential conflict of interest, real or apparent. Members were asked to sign a statement to this effect.
XII. REVIEW OF APPLICATIONS
Grant Review
The Council considered 495 applications requesting $112,939,018 in total costs. The Council recommended 352 applications for a total cost of $77,738,870 (see Attachment II).
ADJOURNMENT
The meeting was adjourned at 4:00 p.m. on January 28, 2005.
CERTIFICATION
I hereby certify that the foregoing minutes are accurate and complete.
________________________ _________________________
Dr. Lawrence A. Tabak Dr. Norman S. Braveman
Chairperson Executive Secretary
National Advisory Dental and National Advisory Dental and
Craniofacial Research Council Craniofacial Research Council
ATTACHMENTS
I. Roster of Council Members
II. Table of Council Actions
III. Director’s Report to the NADCRC, January 2005
NOTE: A complete set of open-portion handouts is available from the Executive Secretary.